# Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

> **NCT00473616** · PHASE1 · TERMINATED · sponsor: **AstraZeneca** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Cancer
- Advanced Solid Malignancies

## Interventions

- **DRUG:** AZD7762
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00473616
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-05
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 60 (ESTIMATED)
- **Why stopped:** Termination of the study was made after a full review of program data and assessment of the current risk-benefit profile.
- **Last updated:** 2011-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00473616

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00473616, "Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT00473616. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*